United States

Maryland

Name of AuthorInstitutional Affiliation
Brave MOffice of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA. michael.brave@fda.hhs.gov
Hung CFThe Johns Hopkins University School of Medicine, Department of Pathology, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, USA.
Koshiol JCancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892-7236, USA. koshiolj@mail.nih.gov
Pazdur ROffice of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA.
Schiffman MDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA. schiffmm@mail.nih.gov
Wacholder SDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA.
Wu TCDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. wutc@jhmi.edu